OrganiGram Seeks European Foothold Through Key Acquisition Vote

Shareholders of Canadian cannabis producer OrganiGram are set to cast a decisive vote today in Toronto. The ballot centers on the proposed acquisition of Berlin-based Sanity Group, a strategic move designed to establish a significant European presence for the company. With backing from influential advisors, the path appears clear for international growth.

Strategic Rationale and Shareholder Backing

The transaction has garnered notable support. Institutional Shareholder Services (ISS), a leading proxy advisory firm, has endorsed the strategic approach. Its analysis suggests the combined entity would benefit from greater scale and enhanced cash flow. Further confidence is signaled by British American Tobacco (BAT), OrganiGram's largest shareholder. A BAT subsidiary is supporting the financing through a private placement of 65.2 million CAD, subscribed at a premium to the market price.

This vote follows unanimous approval from OrganiGram's independent board members, making today's meeting the formal launch point for the integration process.

Should investors sell immediately? Or is it worth buying OrganiGram?

Financial Mechanics of the Deal

The acquisition of Sanity Group represents a substantial financial commitment. OrganiGram has agreed to an upfront payment of 113.4 million euros. This sum comprises 80 million euros in cash, with the remainder settled through the issuance of OrganiGram shares. The total cost could rise significantly based on Sanity Group's performance. An earn-out provision stipulates an additional 113.8 million euros could be payable if the Berlin company achieves specific financial targets in the first year post-closing.

Operational Momentum Supports Expansion

OrganiGram's recent financial performance provides a strong foundation for this ambitious step. For the first quarter of fiscal 2026, the company reported a 49% year-over-year increase in net revenue, reaching 65.3 million CAD. Its adjusted EBITDA showed even more dramatic improvement, surging 273% to 5.3 million CAD.

International operations are already a rapidly growing segment, having posted a 173% revenue increase during fiscal 2025. By integrating Sanity Group, OrganiGram aims to leverage this momentum and solidify its position as a global participant in government-regulated cannabis markets outside Canada.

The company's overarching growth strategy remains ambitious, with a target of achieving annual revenue exceeding 300 million CAD.

Ad

OrganiGram Stock: New Analysis - 30 March

Fresh OrganiGram information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated OrganiGram analysis...

CA68620P1018 | ORGANIGRAM | boerse | 69027903 |